HYTN Lists on the OTC Pink Market
HYTN Innovations Inc. (CSE: HYTN | FSE: 85W0 | OTC PINK: HYTNF), a pharmaceutical company specializing in psychoactive and psychotropic compounds, has announced its approval for trading on the OTC PINK Market effective July 29th, 2024, under the symbol HYTNF. This move is expected to enhance the company's visibility and accessibility to a wider range of investors.
CEO Elliot McKerr stated that this milestone aligns with HYTN's long-term strategic goals for growth and value creation. The company's shares will continue to trade on the Canadian Securities Exchange (CSE) and the Frankfurt Stock Exchange (FSE) under their existing symbols.
HYTN focuses on the formulation, manufacturing, marketing, and sale of products containing cannabis-derived cannabinoids and psilocybe-derived tryptamines, aiming to become a premier provider in federally regulated markets.
HYTN Innovations Inc. (CSE: HYTN | FSE: 85W0 | OTC PINK: HYTNF), un'azienda farmaceutica specializzata in composti psicoattivi e psicotropi, ha annunciato la sua approvazione per il trading sul mercato OTC PINK a partire dal 29 luglio 2024, sotto il simbolo HYTNF. Questa mossa si prevede che aumenterà la visibilità e l'accessibilità dell'azienda a una gamma più ampia di investitori.
Il CEO Elliot McKerr ha dichiarato che questo traguardo è in linea con gli obiettivi strategici a lungo termine di HYTN per la crescita e la creazione di valore. Le azioni dell'azienda continueranno a essere scambiate sulla Borsa canadese (CSE) e sulla Borsa di Francoforte (FSE) sotto i loro simboli esistenti.
HYTN si concentra sulla formulazione, produzione, marketing e vendita di prodotti contenenti cannabinoidi derivati dalla cannabis e triptamine derivate da psilocibe, puntando a diventare un fornitore di primo piano nei mercati regolamentati a livello federale.
HYTN Innovations Inc. (CSE: HYTN | FSE: 85W0 | OTC PINK: HYTNF), una empresa farmacéutica especializada en compuestos psicoactivos y psicotrópicos, ha anunciado su aprobación para negociar en el mercado OTC PINK a partir del 29 de julio de 2024, bajo el símbolo HYTNF. Se espera que este movimiento mejore la visibilidad y accesibilidad de la empresa a una gama más amplia de inversores.
El CEO Elliot McKerr declaró que este hito se alinea con los objetivos estratégicos a largo plazo de HYTN para el crecimiento y la creación de valor. Las acciones de la empresa seguirán negociándose en la Bolsa de Valores de Canadá (CSE) y en la Bolsa de Frankfurt (FSE) bajo sus símbolos existentes.
HYTN se centra en la formulación, fabricación, comercialización y venta de productos que contienen cannabinoides derivados del cannabis y triptaminas derivadas de psilocibes, con el objetivo de convertirse en un proveedor de primer nivel en mercados regulados a nivel federal.
HYTN Innovations Inc. (CSE: HYTN | FSE: 85W0 | OTC PINK: HYTNF)는 향정신성 및 정신작용 화합물에 전문화된 제약 회사로, 2024년 7월 29일부터 OTC PINK 마켓에서 HYTNF 기호로 거래 승인되었다고 발표했습니다. 이 결정은 회사의 가시성과 더 많은 투자자에 대한 접근성을 향상시킬 것으로 예상됩니다.
CEO 엘리엇 맥케르는 이 이정표가 HYTN의 장기 전략 목표인 성장과 가치 창출에 부합한다고 밝혔습니다. 회사의 주식은 기존 기호로 캐나다 증권 거래소 (CSE)와 프랑크푸르트 증권 거래소 (FSE)에서 계속 거래될 것입니다.
HYTN은 대마초에서 유래된 카나비노이드와 사이로시빈에서 유래된 트립타민이 포함된 제품의 공식화, 제조, 마케팅 및 판매에 집중하며, 연방 규제 시장에서 선두 제공업체가 되는 것을 목표로 하고 있습니다.
HYTN Innovations Inc. (CSE: HYTN | FSE: 85W0 | OTC PINK: HYTNF), une entreprise pharmaceutique spécialisée dans les composés psychoactifs et psychotropes, a annoncé son approbation pour négocier sur le marché OTC PINK à partir du 29 juillet 2024, sous le symbole HYTNF. Ce mouvement devrait améliorer la visibilité et l'accessibilité de l'entreprise à un plus large éventail d'investisseurs.
Le PDG Elliot McKerr a déclaré que cette étape est en ligne avec les objectifs stratégiques à long terme de HYTN pour la croissance et la création de valeur. Les actions de l'entreprise continueront à être échangées sur la Bourse de valeurs canadienne (CSE) et la Bourse de Francfort (FSE) sous leurs symboles existants.
HYTN se concentre sur la formulation, la fabrication, le marketing et la vente de produits contenant des cannabinoïdes dérivés du cannabis et des tryptamines dérivées de psilocybes, visant à devenir un fournisseur de premier plan sur les marchés réglementés au niveau fédéral.
HYTN Innovations Inc. (CSE: HYTN | FSE: 85W0 | OTC PINK: HYTNF), ein Pharmaunternehmen, das auf psychoaktive und psychotrope Verbindungen spezialisiert ist, hat seine Genehmigung für den Handel auf dem OTC PINK Markt ab dem 29. Juli 2024 unter dem Symbol HYTNF bekannt gegeben. Dieser Schritt wird voraussichtlich die Sichtbarkeit und Zugänglichkeit des Unternehmens für eine breitere Palette von Investoren erhöhen.
CEO Elliot McKerr erklärte, dass dieser Meilenstein im Einklang mit den langfristigen strategischen Zielen von HYTN für Wachstum und Wertschöpfung steht. Die Aktien des Unternehmens werden weiterhin an der kanadischen Wertpapierbörse (CSE) und der Frankfurter Wertpapierbörse (FSE) unter ihren bestehenden Symbolen gehandelt.
HYTN konzentriert sich auf die Formulierung, Herstellung, Vermarktung und den Verkauf von Produkten, die cannabinoide Verbindungen aus Cannabis und Tryptamine aus Psilocybe enthalten, mit dem Ziel, ein führender Anbieter in bundesregulierten Märkten zu werden.
- Approval for trading on the OTC PINK Market, potentially increasing investor accessibility
- Continued trading on multiple exchanges (CSE, FSE, OTC PINK), enhancing market presence
- Specialization in psychoactive and psychotropic compounds, including cannabis and psilocybin
- None.
VANCOUVER, British Columbia, July 29, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN | FSE: 85W0 | OTC PINK: HYTNF) “HYTN” or “the Company”, a pharmaceutical company specializing in the development, formulation, and manufacturing of products containing psychoactive and psychotropic compounds, including cannabis and psilocybin, is pleased to announce its approval for trading on the OTC PINK Market ("OTC PINK") effective July 29th, 2024, under the trading symbol “HYTNF”.
Elliot McKerr, HYTN Chief Executive Officer, commented, “As HYTN begins trading on the OTC market, the Company is thrilled to enhance its visibility and accessibility to a wider range of investors. This milestone underscores HYTN's dedication to sustained growth and value creation, aligning with the organizations long-term strategic goals.”
The Company notes that its common shares will continue to trade on the Canadian Securities Exchange (“CSE”) under the symbol HYTN and the Frankfurt Stock Exchange (“FSE”) under the symbol 85W0.
About HYTN Innovations Inc.
HYTN Innovations Inc. is a pharmaceutical company that specializes in the formulation, manufacturing, marketing, and sale of products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids and psilocybe-derived tryptamines. HYTN is dedicated to becoming a premier provider of these products across all federally regulated markets. The Company accomplishes this by strategically identifying market opportunities and effectively bringing innovative products to market through its advanced development platform.
For more information contact:
Elliot McKerr
Chief Executive Officer
1.866.590.9289
HYTN Investor Relations:
1.866.590.9289
investments@hytn.life
The Canadian Securities Exchange (CSE) has not reviewed, approved, or disapproved the contents of this press release.
Certain information contained herein may constitute forward-looking statements that involve risks and uncertainties. Readers are cautioned not to place undue reliance on forward-looking statements, including but not limited to statements regarding: (i)the Company trading on the OTC PINK market. (ii) the Company enhancing its visibility to a wider range of investors. (iii) the Company’s common shares continuing to trade on the CSE and FSE. Factors that could cause actual results to vary from forward-looking statements or may affect the operations, performance, development, and results of the Company’s business include, among other things: the Company’s failure to generate sufficient cash flow from operations to meet its current and future obligations; the Company’s failure to access sources of debt and equity capital; changes to the regulatory framework within which the Company operates; competitive factors, pricing pressures, and supply and demand in the Company’s industry; and general economic and business conditions. Any statements that are not statements of historical fact are deemed to be forward-looking statements. The forward-looking statements contained in this news release are made as of the date of this news release, and, except to the extent required by applicable law, the Company assumes no obligation to update or revise forward-looking statements made herein or otherwise, whether because of new information, future events, or otherwise. The forward-looking statements contained in this news release are expressly qualified by this cautionary note.
FAQ
When will HYTN Innovations Inc. start trading on the OTC PINK Market?
What is HYTN Innovations Inc.'s trading symbol on the OTC PINK Market?
What are the main products HYTN Innovations Inc. focuses on?
On which other stock exchanges does HYTN Innovations Inc. trade?
